Minimal Residual Disease in Acute Leukemia:Lessons Learned from Animal Models
Minimal residual disease (MRD) in acute leukemia is defined as the relatively few (1 – 1010) leukemic cells which have survived successful remission-induction chemotherapy. In human acute myelocytic leukemia (AML) there is a significant lack of knowledge on the degree and biological behavior of MRD. However, this is the population of AML cells that determines the failure in the majority of patients:a relapse.
KeywordsAcute Leukemia Minimal Residual Disease Brown Norway Human Acute Myelocytic Leukemia Bone Marrow Compartment
Unable to display preview. Download preview PDF.
- 1.Hagenbeek A, Van Bekkum DW (eds) (1977) Proceedings of an international workshop on Comparative evaluation of the L5222 and the BNML rat leukaemia models and their relevance for human acute leukaemia. Leuk Res 1:75–256Google Scholar
- 6.Van Bekkum DW, Hagenbeek A (1977) Relevance of the BN leukemia as a model for human acute myeloid leukemia. Blood Cells 3:565–572Google Scholar